GlassScriptPhysician profile
Marie S Tuttle
NPI 1356531438
$3,132.86
in general payments reported to CMS, 2019-2025
26 companies · $409 in 2025
The $409 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $455 · 2021: $481 · 2022: $445 · 2023: $337 · 2024: $560 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,267 · Education: $38.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.78 |
| Education | $38.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $565.92 | 2020-2025 | Skyrizi |
| Janssen Biotech, INC. | $532.80 | 2019-2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $245.26 | 2019-2024 | |
| Leo Pharma INC. | $198.40 | 2021-2023 | Adbry |
| Ucb, INC. | $190.90 | 2021-2025 | Bimzelx, Cimzia |
| Biofrontera INC. | $189.25 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $179.83 | 2019-2024 | Jublia |
| Lilly USA, LLC | $147.54 | 2020-2025 | Ebglyss, Taltz, Olumiant |
| Prugen, INC. Pharmaceuticals | $118.63 | 2020 | |
| Celgene Corporation | $116.10 | 2019 | |
| Amgen INC. | $113.05 | 2021-2024 | Otezla |
| Almirall LLC | $80.11 | 2022-2025 | Seysara, Klisyri |
| Vyne Pharmaceuticals INC. | $75.92 | 2021 | |
| Genzyme Corporation | $72.33 | 2019-2024 | |
| Helsinn Therapeutics (U.S.), INC. | $70.14 | 2019-2025 | Valchlor |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $44.12 | 2019-2022 | |
| Medtronic, INC. | $33.61 | 2024-2025 | Venaseal |
| Genentech USA, INC. | $30.13 | 2021-2024 | Erivedge |
| Sun Pharmaceutical Industries INC. | $29.60 | 2019-2022 | |
| Galderma Laboratories, L.P. | $16.47 | 2025 | Aklief |
| Dermavant Sciences, INC. | $16.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $15.59 | 2023 | Libtayo |
| Arcutis Biotherapeutics, INC. | $13.61 | 2025 | Zoryve |
| Merz North America, INC. | $13.33 | 2019 | |
| Tactile Systems Technology INC | $12.98 | 2020 | |
| Dermira, INC. | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Tuttle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.